By Steve Stricker Columnist Dr. Mark Campbell, Autum, Derek, Dorothy (Oxford Stern Cardiovascular Clinic Staff), Vallery, Carlen, Katlan, Madison (In-room preparation and monitoring), Dr. Mark, Derek, ...
HeartBeam (NASDAQ: BEAT) , a medical technology company advancing cardiac care, has submitted a 510 (k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram ( ...
SANTA CLARA, Calif. - HeartBeam, Inc. (NASDAQ: BEAT), a $56.5 million market cap pioneer in medical technology currently trading at $2.12 per share, has announced the submission of a 510(k) ...
The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five clinical sites. The Company believes the study's findings support the clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback